Maintenance. We are currently updating the site. Please check back shortly
Members login
  • TrustLaw
  • Members Portal
Subscribe

U.S. FDA warns against nipple test for breast cancer

Source: Reuters - Thu, 12 Dec 2013 08:23 PM
Author: Reuters
wom-rig hum-dis
Tweet Recommend Google + LinkedIn Bookmark Email Print
Leave us a comment

Dec 12 (Reuters) - A nipple fluid test is not an effective screening tool for breast cancer, U.S. regulators warned on Thursday, noting that mammography is the best way to detect the disease in its earliest, most treatable stages.

The Food and Drug Administration, in a statement to healthcare professionals, said it is concerned that women will believe misleading claims about a nipple aspirate test and not get mammograms or other needed breast imaging tests or biopsies.

The agency noted that it had issued a warning letter earlier this year to Atossa Genetics Inc about its nipple aspirate fluid collection device and process. The company recalled the product in October.

The FDA said it is not aware of any valid scientific data to show that nipple aspirate testing by itself is an effective screening tool for any medical condition.

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of the Thomson Reuters Foundation. For more information see our Acceptable Use Policy.

comments powered by Disqus
TOPICAL CONTENT
Topical content
LATEST SLIDESHOW

Latest slideshow

See allSee all
FEATURED JOBS
Featured jobs